JP2022517109A5 - - Google Patents
Info
- Publication number
- JP2022517109A5 JP2022517109A5 JP2021540533A JP2021540533A JP2022517109A5 JP 2022517109 A5 JP2022517109 A5 JP 2022517109A5 JP 2021540533 A JP2021540533 A JP 2021540533A JP 2021540533 A JP2021540533 A JP 2021540533A JP 2022517109 A5 JP2022517109 A5 JP 2022517109A5
- Authority
- JP
- Japan
- Prior art keywords
- independently
- cancer
- cancers
- alkyl
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962791979P | 2019-01-14 | 2019-01-14 | |
| US62/791,979 | 2019-01-14 | ||
| PCT/US2020/013264 WO2020150115A1 (en) | 2019-01-14 | 2020-01-13 | Nlrp3 modulators |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022517109A JP2022517109A (ja) | 2022-03-04 |
| JP2022517109A5 true JP2022517109A5 (enExample) | 2022-09-05 |
| JP7335341B2 JP7335341B2 (ja) | 2023-08-29 |
Family
ID=69469246
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021540533A Active JP7335341B2 (ja) | 2019-01-14 | 2020-01-13 | Ｎｌｒｐ３モジュレーター |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US12391675B2 (enExample) |
| EP (1) | EP3911641A1 (enExample) |
| JP (1) | JP7335341B2 (enExample) |
| KR (1) | KR102865929B1 (enExample) |
| CN (1) | CN113286786A (enExample) |
| WO (1) | WO2020150115A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12338228B2 (en) | 2019-01-14 | 2025-06-24 | Innate Tumor Immunity, Inc. | NLRP3 modulators |
| CA3229401A1 (en) * | 2021-08-31 | 2023-03-09 | Japan Tobacco Inc. | 6-aminopyrazolopyrimidine compounds and medical use thereof |
| CN115282280A (zh) * | 2022-08-12 | 2022-11-04 | 中国科学技术大学 | TGF-β1信号抑制剂的新用途 |
| IL322520A (en) * | 2023-02-24 | 2025-10-01 | Japan Tobacco Inc | Modified pyrazolopyrimidine compounds and their medical use |
| JP7729000B2 (ja) * | 2023-02-24 | 2025-08-25 | 日本たばこ産業株式会社 | ６－アルコキシピラゾロピリミジン化合物及びその医薬用途 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ302706B6 (cs) | 1998-12-23 | 2011-09-14 | Pfizer Inc. | Lidská monoklonální protilátka, farmaceutická kompozice tuto protilátku obsahující, bunecná linie produkující tuto protilátku, izolovaná molekula kódující težký nebo lehký retezec uvedené protilátky, hostitelská bunka obsahující tuto izolovanou molek |
| EP1212422B1 (en) | 1999-08-24 | 2007-02-21 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
| US7927613B2 (en) | 2002-02-15 | 2011-04-19 | University Of South Florida | Pharmaceutical co-crystal compositions |
| PT1907424E (pt) | 2005-07-01 | 2015-10-09 | Squibb & Sons Llc | Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1) |
| BR122017025062B8 (pt) | 2007-06-18 | 2021-07-27 | Merck Sharp & Dohme | anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento |
| EP3255060A1 (en) | 2008-12-09 | 2017-12-13 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| PL2504364T3 (pl) | 2009-11-24 | 2017-12-29 | Medimmune Limited | Ukierunkowane środki wiążące przeciwko B7-H1 |
| JP6072771B2 (ja) | 2011-04-20 | 2017-02-01 | メディミューン，エルエルシー | Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子 |
| CA2840060A1 (en) | 2011-06-27 | 2013-01-03 | Kyorin Pharmaceutical Co., Ltd. | Bridged bicyclic compounds for the treatment of bacterial infections |
| KR101764096B1 (ko) | 2011-11-28 | 2017-08-02 | 메르크 파텐트 게엠베하 | 항-ｐｄ-ｌ1 항체 및 그의 용도 |
| HK1203971A1 (en) | 2012-05-15 | 2015-11-06 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
| KR20220084444A (ko) | 2012-05-31 | 2022-06-21 | 소렌토 쎄라퓨틱스, 인코포레이티드 | Pd-l1에 결합하는 항원 결합 단백질 |
| SMT202100065T1 (it) | 2013-05-02 | 2021-03-15 | Anaptysbio Inc | Anticorpi diretti contro la proteina della morte programmata (pd-1) |
| PE20160080A1 (es) | 2013-05-18 | 2016-02-21 | Aduro Biotech Inc | Composiciones y metodos para activar la senalizacion que depende del estimulador del gen de interferon |
| WO2014194302A2 (en) | 2013-05-31 | 2014-12-04 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind pd-1 |
| CN112552401B (zh) | 2013-09-13 | 2023-08-25 | 广州百济神州生物制药有限公司 | 抗pd1抗体及其作为治疗剂与诊断剂的用途 |
| SG10201804945WA (en) | 2013-12-12 | 2018-07-30 | Shanghai hengrui pharmaceutical co ltd | Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| PE20170255A1 (es) | 2014-01-24 | 2017-03-22 | Dana Farber Cancer Inst Inc | Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas |
| CN108112254B (zh) | 2015-03-13 | 2022-01-28 | 西托姆克斯治疗公司 | 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法 |
| MA53355A (fr) | 2015-05-29 | 2022-03-16 | Agenus Inc | Anticorps anti-ctla-4 et leurs procédés d'utilisation |
| WO2017024465A1 (en) | 2015-08-10 | 2017-02-16 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
| AR105654A1 (es) | 2015-08-24 | 2017-10-25 | Lilly Co Eli | Anticuerpos pd-l1 (ligando 1 de muerte celular programada) |
| AU2016317915B2 (en) | 2015-09-01 | 2021-02-18 | Agenus Inc. | Anti-PD-1 antibodies and methods of use thereof |
| WO2017132827A1 (en) | 2016-02-02 | 2017-08-10 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
| CN108029076B (zh) | 2016-02-02 | 2020-03-10 | 华为技术有限公司 | 确定发射功率的方法、用户设备和基站 |
| KR20180134395A (ko) * | 2016-04-19 | 2018-12-18 | 인네이트 튜머 이뮤니티, 인코포레이티드 | Nlrp3 조정제 |
| TWI674261B (zh) * | 2017-02-17 | 2019-10-11 | 美商英能腫瘤免疫股份有限公司 | Nlrp3 調節劑 |
| US11344543B2 (en) * | 2017-07-14 | 2022-05-31 | Innate Tumor Immunity, Inc. | NLRP3 modulators |
| WO2020150114A1 (en) * | 2019-01-14 | 2020-07-23 | Innate Tumor Immunity, Inc. | Heterocyclic nlrp3 modulators, for use in the treatment of cancer |
| US12338228B2 (en) * | 2019-01-14 | 2025-06-24 | Innate Tumor Immunity, Inc. | NLRP3 modulators |
-
2020
- 2020-01-13 US US17/422,512 patent/US12391675B2/en active Active
- 2020-01-13 CN CN202080008819.6A patent/CN113286786A/zh active Pending
- 2020-01-13 WO PCT/US2020/013264 patent/WO2020150115A1/en not_active Ceased
- 2020-01-13 KR KR1020217025495A patent/KR102865929B1/ko active Active
- 2020-01-13 JP JP2021540533A patent/JP7335341B2/ja active Active
- 2020-01-13 EP EP20703911.6A patent/EP3911641A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022517109A5 (enExample) | ||
| JP2021534168A5 (enExample) | ||
| JP2021522249A5 (enExample) | ||
| JP2021534158A5 (enExample) | ||
| JP7274450B2 (ja) | 癌を処置するための医薬組合せ | |
| ES2290199T3 (es) | Mezcla que incluye un agente que reduce la actividad de fcve y un agente que reduce la actividad de fce. | |
| JP6404242B2 (ja) | がんの治療のための併用療法としてのエリブリンおよびレンバチニブの使用 | |
| JP2025024006A5 (enExample) | ||
| KR20210075992A (ko) | Sting 작동 화합물 | |
| ES2946472T3 (es) | Agente antitumoral y potenciador del efecto antitumoral | |
| WO2019136298A1 (en) | Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues | |
| JP2022517110A5 (enExample) | ||
| ES2653990T3 (es) | Benzodiazepinas para tratamiento del cáncer de pulmón de células pequeñas | |
| RU2007110480A (ru) | Терапевтические комбинации, содержащие ингибитор поли(адф-рибоза)полимеразы | |
| RU2020113749A (ru) | Аналоги таиланстатина | |
| MX2013008749A (es) | Agente terapeutico o profilactico para caquexia. | |
| CA3080644A1 (en) | Use of parp inhibitor in treating chemotherapy-resistant ovarian cancer or breast cancer | |
| JP2023506787A5 (enExample) | ||
| WO2023114871A1 (en) | Use of combination therapy for treating cancer | |
| WO2021007402A1 (en) | Peptide conjugates of microtubule-targeting agents as therapeutics | |
| RU2013143520A (ru) | Новые химические соединения (варианты) и их применение для лечения онкологических заболеваний | |
| ES2440799T3 (es) | Métodos para tratar cáncer resistente a los fármacos | |
| JP2024542633A5 (enExample) | ||
| RU2334517C2 (ru) | Средство, потенцирующее противоопухолевый эффект, и противоопухолевое средство | |
| JP2022502378A5 (enExample) |